BIIB vs. BMY: Biogen vs. Bristol-Myers Squibb Stock Comparison

Company Profile

Biogen (BIIB) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Biogen (BIIB) at 1.87% is closer to the peer norm — stronger capital efficiency for BMY.

Bristol-Myers Squibb (BMY) at 18.47% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

Both Biogen (BIIB) at 24.12% and Bristol-Myers Squibb (BMY) at 33.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Biogen (BIIB) at 2.22% and Bristol-Myers Squibb (BMY) at -0.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Biogen (BIIB) reports EPS growth of -21.38%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Biogen (BIIB) at 1.95 and Bristol-Myers Squibb (BMY) at 1.59 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Biogen (BIIB) at 0.41 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Biogen (BIIB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Biogen (BIIB) at 1.94 and Bristol-Myers Squibb (BMY) at 5.43 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics